Navigation Links
Lilly Declares Second-Quarter Dividend
Date:4/21/2008

INDIANAPOLIS, April 21 /PRNewswire-FirstCall/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) today declared a dividend for the second quarter of 2008 of $0.47 a share on outstanding common stock. This is the same dividend as was paid in the first quarter and maintains the annual indicated dividend rate for 2008 of $1.88 per share.

The dividend is payable June 10, 2008, to shareholders of record at the close of business on May 15, 2008.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com . F-LLY

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Lilly to Streamline Indianapolis Manufacturing and Engineering Operations
2. Lilly Adjusts Time of Conference Call for First Quarter 2008 Financial Results Announcement
3. Lilly Sets Date and Conference Call for First Quarter 2008 Financial Results Announcement
4. State of Alaska and Eli Lilly and Company Reach Agreement to Settle Zyprexa Lawsuit
5. Statement from Eli Lilly and Company: Response to Todays New York Times Article, Lilly E-Mail Discussed Off-Label Drug Use
6. Lilly Grants $4.4 Million to the WHO for MDR-TB Program Expansion
7. Newly Labeled Therapies for Neuropathic Pain, Including Drugs From Pfizer and Eli Lilly, Will Drive Growth in the Chronic Pain Drug Market
8. Mental Health Parity Laudable, But House Legislation Would Put Medicaid Patients at Risk, Lilly Says
9. FDA Issues Not-Approvable Letter for Lillys Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
10. Lilly and Partners In Health, Brigham and Womens Hospital Team Up to Fight MDR-TB in Former Soviet Republics
11. Michael L. Eskew Elected to Lilly Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... NucleusHealth ™, advancing clinical ... U.S. Food and Drug Administration (FDA) 510(k) clearance for its ... platform for medical image management. At the core is patented streaming technology that ...
(Date:5/24/2017)... Cortland, OH (PRWEB) , ... May 24, 2017 , ... ... in Cortland, OH, can now meet with Dr. Joseph Bedich for a consultation, ... smiles while simultaneously improving their oral health and functionality. , Dr. Bedich ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Curry Leavitt, a noted ... Periodontal Practice) continuing education (CE) series. As a compassionate and dedicated clinician, Dr. ... attending numerous CE courses each year. His recent course, Course II of HP3, ...
(Date:5/24/2017)... ... May 24, 2017 , ... Accordant ... its solutions portfolio. ExtraHop delivers an analytics-first approach, layered with machine learning, that ... from the datacenter to the cloud to the edge. Through the new partnership, ...
(Date:5/24/2017)... ... 2017 , ... Rob Lowe is a sought after actor, and also serves ... the public important topics from all aspects of life, and a new segment is ... feet and ankles. , Podiatry is essential to people’s overall well-being, and if viewers ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... 10, 2017 Radiology has become the number ... have also spiraled to the number one ranking as ... than ever before as the most complete and reliable ... with lower back pain an MRI may confirm a ... pain, resulting in entirely different treatment protocols.  In these ...
(Date:5/9/2017)... , May 9, 2017  Oramed Pharmaceuticals Inc. ... a clinical-stage pharmaceutical company focused on the development ... the Canadian Intellectual Property Office has granted Oramed ... Administration of Exenatide". The patent covers Oramed,s invention ... GLP-1 is an incretin hormone that stimulates ...
(Date:5/6/2017)... --  Provista , a proven leader in the supply chain ... Jim Cunniff as the company,s new president and ... to Provista, including most recently serving as the president and ... . He assumed his new role with Provista on May ... Provista," says Jody Hatcher , president, Sourcing and Collaboration ...
Breaking Medicine Technology: